[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339043-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-339043-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","adjuvant-novel-nanocarrier-based-targeted-therapy-for-lung-cancer","Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer","","Lung cancer remains highly lethal due to late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity that collectively reduce treatment effectiveness. Tumor microenvironment signaling via chemokines and cytokines further complicates therapy. This review focuses on nanocarrier-based adjuvant strategies aimed at improving targeting and therapeutic performance within the tumor microenvironment (TME). It discusses biofunctionalized delivery systems that promote biosystem interaction, cellular uptake, immune evasion, and vascular modifications, including photothermal ROS scavenging by inorganic metal compounds. It also covers modulation of ECM, cancer-associated fibroblasts, TAM receptor pathways, Treg and MDSC inhibition, and enhanced active targeting using biomimetic or ligand-functionalized nanocarriers, supporting NSCLC-targeted therapy with complex-loaded organic drugs and inorganic metal components.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/adjuvant-novel-nanocarrier-based-targeted-therapy-for-lung-cancer/339043/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/adjuvant-novel-nanocarrier-based-targeted-therapy-for-lung-cancer/339043.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why does lung cancer have low survival rates?","Question",{"text":62,"@type":63},"Low survival is linked to late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity, all of which reduce treatment effectiveness.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What role do nanocarriers play in improving therapy for lung cancer?",{"text":67,"@type":63},"Nanocarriers are used to enhance targeted chemotherapeutic delivery and pathway blocking in the tumor microenvironment, improving interaction, cellular uptake, immune escape, and vascular changes.",{"name":69,"@type":60,"acceptedAnswer":70},"How do inorganic metal compounds contribute to nanocarrier therapy?",{"text":71,"@type":63},"They can scavenge reactive oxygen species (ROS) through photothermal effects, supporting improved therapeutic outcomes in the TME.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},339043,1790638118,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":101,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","molecules   \nReview  \nAdjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer  \nKangkan Sarma 1, Md Habban Akther 1, *, Irfan Ahmad 2, *, Obaid Afzal 3, Abdulmalik S. A. Altamimi 3, Manal A. Alossaimi 3, Mariusz Jaremko 4, Abdul-Hamid Emwas 5 and Preety Gautam 1  \nCitation: Sarma, K.; Akther, M.H.; Ahmad, I.; Afzal, O.; Altamimi,  \nA.S.A.; Alossaimi, M.A.; Jaremko, M.; Emwas, A.-H.; Gautam, P. Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer. Molecules 2024, 29, 1076. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/molecules29051076](10.3390/molecules29051076)  \nAcademic Editor: Maria Camilla Bergonzi  \nReceived: 25 May 2023  \nRevised: 19 July 2023  \nAccepted: 25 July 2023  \nPublished: 29 February 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 School of Pharmaceutical and Population Health Informatics (SoPPHI), DIT University, Dehradun 248009, India; [sarma_kangkan@outlook.com](sarma_kangkan@outlook.com) (K.S.); [1000015383@dit.edu.in](1000015383@dit.edu.in) (P.G.)  \n2 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha 62521, Saudi Arabia  \n3 Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia; [o.akram@psau.edu.sa](o.akram@psau.edu.sa) (O.A.); [as.altamimi@psau.edu.sa](as.altamimi@psau.edu.sa) (A.S.A.A.); [m.alossaimi@psau.edu.sa](m.alossaimi@psau.edu.sa) (M.A.A.)  \n4 Smart-Health Initiative (SHI) and Red Sea Research Center (RSRC), Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia; [mariusz.jaremko@kaust.edu.sa](mariusz.jaremko@kaust.edu.sa)  \n5 Core Labs, King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia; [abdelhamid.emwas@kaust.edu.sa](abdelhamid.emwas@kaust.edu.sa)  \n* [Correspondence: habban.akhter@dituniversity.edu.in or habban2007@gmail.com](Correspondence: habban.akhter@dituniversity.edu.in or habban2007@gmail.com) (M.H.A.); [irfancsmmu@gmail.com](irfancsmmu@gmail.com) (I.A.)  \nAbstract: Lung cancer has the lowest survival rate due to its late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity. These factors decrease the effectiveness of treatment. They release chemokines and cytokines from the tumor microenvironment (TME) . To improve the effectiveness of treatment, researchers emphasize personalized adjuvant therapies along with conventional ones. Targeted chemotherapeutic drug delivery systems and specific pathway-blocking agents using nanocarriers are a few of them. This study explored the nanocarrier roles and strategies to improve the treatment profile’s effectiveness by striving for TME. A biofunctionalized nanocarrier stimulates biosystem interaction, cellular uptake, immune system escape, and vascular changes for penetration into the TME. Inorganic metal compounds scavenge reactive oxygen species (ROS) through their photothermal effect. Stroma, hypoxia, pH, and immunity-modulating agents conjugated or modified nanocarriers co-administered with pathway-blocking or condition-modulating agents can regulate extracellular matrix (ECM), Cancer-associated fibroblasts (CAF),Tyro3, Axl, and Mertk receptors (TAM) regulation, regulatory T-cell (Treg) inhibition, and myeloid-derived suppressor cells (MDSC) inhibition. Again, biomimetic conjugation or the surface modification of nanocarriers using ligands can enhance active targeting efficacy by bypassing the TME. A carrier system with biofunctionalized inorganic metal compounds and organic compound complex-loaded drug","cbCaigXzKivsPj5X","https://ap.wps.com/l/cbCaigXzKivsPj5X","pdf",5810383,51,"English","# Abstract\n# Introduction\n## Global burden and survival rates\n## Etiology and risk factors\n# Review focus: nanocarrier strategies for adjuvant targeted therapy","[{\"question\":\"Why does lung cancer have low survival rates?\",\"answer\":\"Low survival is linked to late-stage diagnosis, poor prognosis, and intra-tumoral heterogeneity, all of which reduce treatment effectiveness.\"},{\"question\":\"What role do nanocarriers play in improving therapy for lung cancer?\",\"answer\":\"Nanocarriers are used to enhance targeted chemotherapeutic delivery and pathway blocking in the tumor microenvironment, improving interaction, cellular uptake, immune escape, and vascular changes.\"},{\"question\":\"How do inorganic metal compounds contribute to nanocarrier therapy?\",\"answer\":\"They can scavenge reactive oxygen species (ROS) through photothermal effects, supporting improved therapeutic outcomes in the TME.\"}]","Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer | PDF",1790027476,129,[147,151,155,159,163,167],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff76891eb46a01fb567f52f14e042e66.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a570d9a1bd1d8583a03545c42e4dbf5.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f95c83607116bd399884a8ef5f5c683f.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77cdf7e1ccc5a8940505d68eb4158cce.webp",980,1385,{"page_no":96,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db4a0b33e574544ca7dc6c254e480b29.webp",979,1384,{"page_no":101,"url":168,"width":169,"height":170},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f228673c4b3a325d698761a8162d05ad.webp",978,1383]